Increased expression of CIP2A in cholangiocarcinoma and correlation with poor prognosis

Hepato-Gastroenterology

Volumn 60, Issue 124, 2013, Pages 669-672

  Xu, Peng ^a   Huang, Qiang ^a   Xie, Fang ^a   Xu, Xiao Lan ^a   Shao, Feng ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Cholangiocarcinoma; CIP2A; Immunohistochemical staining; Prognosis

Indexed keywords

CANCEROUS INHIBITOR OF PHOSPHOPROTEIN PHOSPHATASE 2A; PHOSPHOPROTEIN PHOSPHATASE 2A; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BILE DUCT CARCINOMA; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; AUTOANTIGENS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84879572982     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge11139     Document Type: Article

References (16)

1. Huang ZQ: The status of surgical treatment of cholangiocarcinoma. Chin J Practical Surg 2007; 27:341-346. [In Chinese with English abstract]
2. Zhao P, Lu Y, Zhong M, et al.: Inverse correlation of aberrant expression of fragile histidine triad (FHIT) protein with cyclin D1 protein and prognosis in Chinese patients with cholangiocarcinoma. Acta Oncologica 2008; 47:1557-1563.
3. Baek S, Lee YW, Yoon S, et al.: CDH3/P-Cadherin regulates migration of HuCCT1 cholangiocarcinoma cells. Anatomy Cell Biology 2010; 43:110-117.
4. Zhou YM, Yin ZF, Yang JM, et al.: Risk factors for intrahepatic cholangiocarcinoma: A case-control study in China. World J Gastroenterol 2008; 14:632-635.
5. Bo F, Fei W, Y Tian, et al.: Characteristic analysis on hepatitis B virus (HBV) infection model. Chinese Frontier Health Quarantine 2010; 33:232-234. [In Chinese with English abstract]
6. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000; 100:57-70. (Pubitemid 30046295)
7. Soo Hoo L, Zhang JY, Chan EK: Cloning and Characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer. Oncogene 2002; 21:5006-5015.
8. Li W, Ge Z, Liu C, et al.: CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells. Clin Cancer Res 2008; 14:3722-3728.
9. Khanna A, Bockelman C, Hemmes A, et al.: MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst 2009; 101:793-805.
10. Come C, Laine A, Chanrion M, et al.: CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res 2009; 15:5092-5100.
11. Junttila MR, Puustinen P, Niemela M, et al.: CIP2A inhibits PP2A in human malignancies. Cell 2007; 130:51-62. (Pubitemid 47039258)
12. Basile JR, Czerninski R: The role of CIP2A in oral squamous cell carcinoma. Cancer Biol Ther 2010; 10:700-702.
13. Dong QZ, Wang Y, Dong XJ, et al.: CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Ann Surg Oncol 2011; 18(3):857-865.
14. Vaarala MH, Vaisanen MR, Ristimaki A: CIP2A expression is increased in prostate cancer. J Exp Clin Cancer Res 2010; 29:136.
15. K-F Chen, C-Y Liu, Y-C Lin, et al.: CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. Oncogene 2010; 29:6257-6266.
16. Zhao D, Liu Z, Ding J, et al.: Helicobacter pylori CagA upregulation of CIP2A isdependent on the Src and MEK/ERK pathways. J Med Microbiol 2010; 59:259-265.